Clinical trials: Hepatitis C, completed
HCV Infection
Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
The primary objective of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of a single dose of voxilaprevir (formerly GS-9857) in participants with normal hepatic function, moderate hepatic impairment…
- Trial name
- NCT02397707
- Testing
- Voxilaprevir
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Hepatitis C
Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs
This study is designed to obtain and store samples of serum and liver tissue in HCV (HepC Virus)-infected patients being treated with direct-acting antiviral (DAA) therapy, and to determine the effect of new DAA therapies on…
- Trial name
- NCT02532907
- Testing
- Liver Biopsy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Colorado, Denver
Hepatitis C, Chronic
A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.
The purpose of this study is to determine whether a 10-day course of therapy with orally administered VCH-759 given at 400-mg, 600-mg or 800-mg three times daily can effectively reduce the amount of circulating virus (i.e., viral…
- Trial name
- NCT00389298
- Testing
- VCH-759 (BCH-27759)
- Where
- 4 sites in Canada
- Volunteers
- 36 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C
Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)
Open label phase 2a study of two week treatment with CDI-31244 and sofosbuvir and veltapasvir followed by four week treatment of sofosbuvir and velpatasvir in individuals with chronic hepatitis C (HCV) genotype 1 (GT1) infection
- Trial name
- NCT03501550
- Testing
- CDI-31244, SOF/VEL
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Cocrystal Pharma, Inc.
HIV, Hepatitis C
Effects of Motivational Interviewing on Risky Injecting Practices Among Injecting Drug Users (IDUs)
The purpose of this study is to evaluate the effects of a brief motivational intervention in reducing risky injection practices among injecting drug users (IDUs).
- Trial name
- NCT00794391
- Testing
- Motivational interviewing, Educational intervention
- Where
- Canada
- Volunteers
- 219 people
- Sponsor
- Université de Sherbrooke
Hepatitis C, Chronic, Opioid-use Disorder
Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection
Incorporating Hepatitis C Virus (HCV) treatment into opioid maintenance treatment program clinical protocols is an innovative health care delivery model that has been associated with improved HCV treatment uptake in non-pregnant…
- Trial name
- NCT03057847
- Testing
- Sofosbuvir/Velpatasvir
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Elizabeth Krans, MD
Hepatitis C, Chronic, HIV Infection
Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen
This phase II, multicentric, national pilot trial is designed to estimate the sustained virological response rate (SVR) following a 12 weeks treatment by telaprevir combined with a 48 or 72 weeks treatment by peginterferon and…
- Trial name
- TelapreVIH (NCT01332955)
- Testing
- Telaprevir, pegIFN alfa-2a, Ribavirin
- Where
- France
- Volunteers
- 70 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C, Oral Manifestations
A Cross Sectional Observational Study on Relation Between Oral Manifestation and Hepatitis C in Egypt
Hepatitis C virus (HCV) is the major cause of chronic liver disease and has a long-term resultant complications4 and it considered as a major endemic medical health problem in Egypt.
- Conditions
- Hepatitis C, Oral Manifestations, in Egyptian Population
- Trial name
- NCT04812990
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Misr University for Science and Technology
Hepatitis C
TMC435 HPC1004 - Phase I Study Investigating the Pharmacokinetics of TMC435 in Healthy Chinese Volunteers
The purpose of this study is to assess the pharmacokinetics, safety and tolerability of single and multiple oral doses of TMC435 in Chinese healthy volunteers.
- Trial name
- NCT01224197
- Testing
- TMC435
- Where
- Hong Kong
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C Virus Genotype-1
A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1
The purpose of this study is to evaluate the safety and tolerability of TMC435 along with pegylated interferon alpha-2a (PegIFNα-2a) and ribavirin (RBV) triple therapy in hepatitis C virus genotype-1 infected subjects…
- Trial name
- NCT01479868
- Testing
- TMC435, Pegylated interferon alpha-2a, Ribavirin
- Where
- 32 sites in United States, Canada and 6 more
- Volunteers
- 109 people
- Sponsor
- Janssen R&D Ireland
Hepatitis C, Chronic, Cognition Disorders
Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)
Patients with HCV infection often suffer from chronic fatigue, depression and reduced cognition, even before evolving severe liver fibrosis, liver cirrhosis and hepatic encephalopathy.
- Conditions
- Hepatitis C, Chronic, Cognition Disorders, Fatigue Syndrome, Chronic, Major Depressive Disorder
- Trial name
- NCT00788918
- Testing
- Interferon and ribavirin
- Where
- Denmark
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Hepatitis C, Renal Insufficiency, Chronic
HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant
The purpose of this study is to determine whether patients treated for chronic hepatitis C (HCV) with zepatier (grazoprevir/elbasvir) prior to kidney transplant will have a stronger immune response compared to patients treated…
- Conditions
- Hepatitis C, Renal Insufficiency, Chronic, Disorder of Transplanted Kidney
- Trial name
- NCT02902120
- Testing
- Post-transplant Grazoprevir and Elbasvir
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Maryland, Baltimore
Hepatitis C
Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin
The primary purpose is to assess the effect of Daclatasvir (DCV)/Asunaprevir (ASV)/BMS-791325 combination therapy on the exposure of Rosuvastatin.
- Trial name
- NCT02104843
- Testing
- Daclatasvir, Asunaprevir and BMS-791325 FDC, BMS-791325, Rosuvastatin
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)
The objective of this study is to evaluate the efficacy of three regimens of pegylated interferon-alfa 2b (PEG-IFN) either as monotherapy or in combination with ribavirin in participants with acute hepatitis C.
- Trial name
- NCT00686517
- Testing
- Pegylated interferon alfa-2b, Ribavirin
- Volunteers
- 130 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis
This Phase II, open-label, parallel-arm study will evaluate the safety, tolerability, pharmacokinetics and antiviral activity of ritonavir-boosted danoprevir in combination with Pegasys (peginterferon alfa-2a) and Copegus…
- Trial name
- NCT01749150
- Testing
- danoprevir + ritonavir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
- Where
- 13 sites in South Korea, Taiwan and 1 more
- Volunteers
- 61 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C,Chronic Children, Only
Twelve Weeks Sofosbuvir/Daclatasvir in HCV Infected Children Aged 6-18 Years
Recently the era of direct-acting antiviral drugs for hepatitis C treatment has changed the world map of HCV. Results in adults are promising. FDA approved only two drugs in the pediatric age group 12 to 17 years.
- Trial name
- NCT07905989
- Testing
- Sofosbuvir/Daclatasvir
- Where
- Egypt
- Volunteers
- 42 people
- Sponsor
- National Liver Institute, Egypt
Chronic Hepatitis C, Cirrhosis
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection
The purpose of this study is to evaluate the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in US veterans with genotype 1 chronic hepatitis C virus infection.
- Conditions
- Chronic Hepatitis C, Cirrhosis, Hepatitis C Virus
- Trial name
- NCT02442284
- Testing
- ombitasvir/paritaprevir/ritonavir and dasabuvir, Ribavirin
- Volunteers
- 99 people
- Sponsor
- AbbVie
Encephalitis
Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid
AVI-4020 Injection, a phosphorodiamidate Morpholino oligomer (PMO), was found to cross the blood-brain barrier during a study of patients with presumptive West Nile virus disease.
- Trial name
- NCT00381433
- Testing
- AVI-4065 Injection
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) for 12 weeks in adults with chronic genotype 1, 2, 4, 5, or 6 hepatitis…
- Trial name
- ASTRAL-1 (NCT02201940)
- Testing
- SOF/VEL
- Where
- 80 sites in United States, Belgium and 7 more
- Volunteers
- 741 people
- Sponsor
- Gilead Sciences
Hepatitis C, HCV
TD-6450 MAD Study in HCV Infected Subjects
This proof of concept study is designed to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of TD-6450 in treatment naïve subjects with GT-1, GT-2 or GT-3 chronic HCV.
- Trial name
- NCT02116543
- Testing
- TD-6450
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Theravance Biopharma